All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.97 [0.73 ; 1.29 ] COALITION II Covid-19 Brazil (Furtado), 2020, HYDRA (Hernandez-Cardenas), 2021 2 16% 611 moderate not evaluable deathsdetailed results Cao, 2020 0.71 [0.36; 1.40]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
Galan, 2021 0.94 [0.51; 1.73]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
0.86 [0.74 ; 1.00 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Galan, 2021, HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 7 0% 2,265 moderate not evaluable deaths (time to event analysis only)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
Galan, 2021 0.94 [0.51; 1.73]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
0.85 [0.71 ; 1.03 ] COALITION II Covid-19 Brazil (Furtado), 2020, Galan, 2021, HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 5 21% 1,830 moderate not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
0.95 [0.55 ; 1.64 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
0.96 [0.68 ; 1.35 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 4 68% 1,040 moderate not evaluable clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
0.94 [0.68 ; 1.30 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 5 62% 1,883 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 1.59 [0.84; 3.03]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
1.10 [0.64 ; 1.90 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 3 68% 832 moderate not evaluable clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
1.01 [0.68 ; 1.50 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 3 1% 832 moderate not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
1.19 [0.98 ; 1.45 ] Cao, 2020, CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 2021 3 0% 451 moderate not evaluable hospital dischargedetailed results HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
0.82 [0.66 ; 1.02 ] HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 3 40% 1,265 moderate not evaluable mechanical ventilationdetailed results Galan, 2021 0.14 [0.03; 0.71]
0.14 [0.03 ; 0.71 ] Galan, 2021 1 0% 168 NA not evaluable ICU admissiondetailed results Galan, 2021 1.42 [0.68; 2.99]
1.42 [0.68 ; 2.99 ] Galan, 2021 1 0% 168 NA not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
0.90 [0.59 ; 1.38 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 5 47% 1,872 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
0.36 [0.13 ; 1.01 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
1.09 [0.42 ; 2.79 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable long QTdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
0.90 [0.56 ; 1.43 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.44 [0.98 ; 2.10 ] CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 672 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 06:38 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290